ストックスクリーナーアプリを入手
0.5562
4.61%
0.0245
アフターアワーズ：
.56
0.0038
+0.68%
前日終値:
$0.5317
開ける：
$0.5
24時間の取引高:
1.47M
Relative Volume:
1.38
時価総額：
$93.72M
収益：
-
当期純損益:
$-101.17M
株価収益率:
-0.5348
EPS:
-1.04
ネットキャッシュフロー:
$-96.57M
1週間 パフォーマンス:
+11.80%
1か月 パフォーマンス:
-10.46%
6か月 パフォーマンス:
-51.63%
1年 パフォーマンス:
-41.19%
1日の値動き範囲:
$0.50
$0.56
1週間の範囲:
$0.496
$0.56
52週間の値動き範囲:
$0.4721
$1.60
X 4 Pharmaceuticals Inc Stock (XFOR) Company Profile
名前
X 4 Pharmaceuticals Inc
セクター
電話
857-529-8300
住所
61 NORTH BEACON STREET, BOSTON, MA
X 4 Pharmaceuticals Inc Stock (XFOR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-08-30 | 再開されました | B. Riley Securities | Buy |
| 2022-12-22 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-12-12 | 開始されました | Piper Sandler | Overweight |
| 2019-12-23 | 開始されました | Oppenheimer | Outperform |
| 2019-12-18 | 開始されました | ROTH Capital | Buy |
| 2019-12-09 | アップグレード | Citigroup | Neutral → Buy |
| 2019-12-05 | 開始されました | B. Riley FBR | Buy |
| 2019-06-07 | 開始されました | Stifel | Buy |
| 2019-06-05 | 開始されました | Cowen | Outperform |
すべてを表示
X 4 Pharmaceuticals Inc (XFOR) 最新ニュース
Rigel Announces Six Poster Presentations at the 66th American Society of Hematology Annual Meeting and Exposition - Quantisnow
Top 50 Pharma: Oncology patent leaders 2024 - Drug Discovery & Development
Ionis announces FDA acceptance of New Drug Application for donidalorsen for prophylactic treatment of HAE - Quantisnow
H.C. Wainwright reiterated coverage on Viking Therapeutics with a new price target - Quantisnow
Clearside Biomedical Appoints Tony Gibney as New Chair of the Board of Directors - The Manila Times
Viking Therapeutics Reports New Data from VK2735 Obesity Program at ObesityWeek® 2024 - PR Newswire
Sun Pharma shares tumble 4% as US court blocks Leqselvi launch - The Economic Times
ORIC® Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Lipella Pharmaceuticals Announces 1-for-8 Reverse Stock Split - The Manila Times
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - cnhinews.com
2024's 10 Best-Performing Stocks | Investing - U.S News & World Report Money
Layoff Tracker: Compass Pathways to Lay Off 30% of Employees - BioSpace
Arrowhead Pharmaceuticals Launches New Disease Awareness Campaign, ‘We’ll Get There Soon,’ to Inspire Hope for the Rare Disease Community Affected by Familial Chylomicronemia Syndrome - The Bakersfield Californian
Hypothyroidism Market to Expand by USD 789.8 Million (2024-2028) as New Drug Approvals Drive Revenue; Report Highlights AI's Role in Market TransformationTechnavio - The Malaysian Reserve
Mirum Pharmaceuticals to Showcase LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual Meeting - Business Wire
MIRA Pharma up 27% on ketamine analogue’s preclinical results for chemotherapy pain - Mugglehead
Acute Respiratory Distress Syndrome (ARDS) Market Statistics, Emerging Trends, Key Drivers And Forecast To ... - WhaTech
SEC Form 424B5 filed by Eledon Pharmaceuticals Inc. - Quantisnow
SG Americas Securities LLC Makes New Investment in X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) - Defense World
Block Deal Today: Pharma stock tanks 4% after stake sale worth Rs 3,000 crore by promoter - ET Now
Innovations in Pediatric Bladder Treatment: Shaping a Healthier Future As Discussed In New Market Research ... - WhaTech
Cyclic Heavy Menstrual Bleeding Market Advancements Highlighted by Research And Strategies For Expansion 20... - WhaTech
Acromegaly Market Innovations Investigated by Size, Share, Trends And Outlook Report 2024-2033 - WhaTech
Duchenne Muscular Dystrophy Therapeutics Market Trends, Growth Insights, and Forecasts 2033 - WhaTech
Revenues Not Telling The Story For EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) After Shares Rise 52% - Simply Wall St
Pituitary Dwarf Treatment Global Market Overview In Latest Study - WhaTech
Report Probes the Iron Deficiency Injectable Global Market Research - WhaTech
Basal Cell Carcinoma Treatment Market Analysis, Advancements, and Growth Potential - WhaTech
Alopecia Market Key Trends, Latest Insights, Future Trends And Forecast To 2033 - WhaTech
The Evolution of Narcotic Drugs: Trends and Market Insights In New Report - WhaTech
X4 Pharmaceuticals (NASDAQ:XFOR) vs. Tectonic Therapeutic (NASDAQ:TECX) Critical Analysis - Defense World
Russia is getting Nvidia AI chips from an Indian pharma company - The Times of India
Phathom Pharmaceuticals to Present VOQUEZNA® Data at the American College of Gastroenterology (ACG) 2024 Annual Meeting - The Manila Times
Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics Market Size, Share And Forecast To 2033 - WhaTech
Director Singleton J Matthew exercised 16,000 shares at a strike of $4.48 and sold $1,272,000 worth of shares (16,000 units at $79.50) (SEC Form 4) - Quantisnow
Pack-Smart Inc. to Showcase innovative Delta-X Solutions for Pharmaceutical Supply Chains at PACK EXPO International 2024 - Healthcare Packaging
Global WHIM Syndrome Management Market Projected to Reach USD 17.91 Million by 2033 with a Strong CAGR of 6% - PharmiWeb.com
Malignant Melanoma Treatment Market 2024Industry Size, Business Segments, Innovative Strategies And Outl... - WhaTech
Q3 2024 update: patent activity in the pharmaceutical industry - Pharmaceutical Technology
X4 Pharmaceuticals to Report Third-Quarter 2024 Financial - GlobeNewswire
X4 Pharmaceuticals to Report Third-Quarter 2024 Financial and Phase 2 Chronic Neutropenia Study Results During Conference Call and Webcast on November 13, 2024 - The Manila Times
VRTX: 3 Pharma Stocks to Watch as Gene Therapy Gains Momentum - StockNews.com
Viking Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - PR Newswire
Ionis to hold third quarter 2024 financial results webcast - Quantisnow
SpringWorks Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024 - Quantisnow
Renal Cancer Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - Barchart
Atypical Chemokine Receptor 3 Market to Drive Growth with - openPR
WAINZUA (eplontersen) recommended for approval in the EU by CHMP for the treatment of adults with polyneuropathy associated with hereditary transthyretin-mediated amyloidosis - Quantisnow
Astellas' VYLOY™ (zolbetuximab-clzb) Approved by U.S. FDA for Treatment of Advanced Gastric and GEJ Cancer - PR Newswire
EVP Research Swayze Eric converted options into 125 shares and sold $2,031 worth of shares (53 units at $38.31) (SEC Form 4) - Quantisnow
X 4 Pharmaceuticals Inc (XFOR) 財務データ
収益
当期純利益
現金流量
EPS
2.02%
0.47%
大文字化:
|
ボリューム (24 時間):